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ABSTRACT 
Several studies have evaluated the role of polymorphisms in the promoter region of APOE gene that encodes 
apolipoprotein E (APOE) and the susceptibility to Alzheimer’s disease (AD). The aim of this literature review and 
meta-analysis was to investigate the relationship between the APOE promoter region single nucleotide polymor-
phisms (SNPs) (rs449647, -491A/T; rs769446, -427T/C and rs405509 -219T/G) and the risk of developing AD. 
Eligible controlled studies published up to November 2016 were retrieved from main online scientific and medical 
databases. Odds ratio (OR) and 95 % confidence interval (CI) were used to calculate the strength of the relation-
ship. A total of 23 publications (19 for rs449647, ten for rs769446 and ten for rs405509) were retrieved that in-
cluded 5,703 patients with AD and 5,692 controls. The C allele of the rs769446 variant of the promoter region of 
APOE gene was significantly associated with an increase of risk of AD (OR = 1.271, 95 % CI = 1.114–1.449, P < 
0.0001), while other genetic models of this variant were not related with susceptibility to AD. Rs449647 and 
rs405509 polymorphisms of APOE gene were not associated with an increase of risk of AD. The findings of this 
literature review and meta-analysis have shown that rs769446 polymorphism in the promoter region of APOE gene 
could be a risk factor for AD. Future large-scale studies on the role of polymorphisms in the promoter region of 
APOE gene in AD are still awaited.  
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INTRODUCTION 
Alzheimer’s disease (AD) is a chronic and 
progressive neurodegenerative disease that 
usually starts slowly and becomes more se-
vere over time (Ballard et al., 2011; Vinters, 
2015). Worldwide, AD is now the leading 
cause of dementia in late adult life, account-
ing for 60 % to 70 % of all cases of dementia 
(Mayeux and Stern, 2012). The most common 
symptoms include cognitive impairment, loss 
of short-term memory, problems with lan-
guage, disorientation, mood swings, loss of 
motivation, and behavioral issues (Geda et al., 
2013). According to the 2016 data from the 
Alzheimer’s Association, an estimated 5.4 
million Americans have AD, and approxi-
mately 700,000 Americans age ≥ 65 years 
will die with this disease in 2016 (Alz-
heimer’s Association, 2016). Furthermore, by 
2050, one new case of Alzheimer’s is ex-
pected to develop every 33 seconds, resulting 
in nearly 1 million new cases per year (Reitz 
and Mayeux, 2014; Sosa-Ortiz et al., 2012).  
However, the etiology of AD remains un-
clear. Although there are now several drugs 
that can be used in the treatment of AD, ran-
domized controlled clinical trials have yet to 
show robust treatment benefits (Gandy and 
Dekosky, 2013). Also, the study of the long-
term effect of any intervention for patients 
with AD is a great methodological challenge 
(Wimo, 2015). Therefore, there is an urgent 
need to identify biomarkers that can predict 
this disease and guide therapeutic strategies.  
AD is a heterogeneous disease, and about 
70 % of the risk is believed to be genetic with 
many genes involved (Karch et al., 2014). The 
APOE gene that encodes apolipoprotein E 
(ApoE) located on human chromosome 19 is 
a multifunctional protein and is a major cho-
lesterol carrier with central roles in lipid me-
tabolism, neurobiology, and neurodegenera-
tive diseases (Carrasquillo et al., 2013; 
Hatters et al., 2006). The APOE gene has been 
recognized as a possible genetic risk factor for 
the onset of AD (Yu et al., 2014). There are 
known to be three isoforms (ε2, ε3, and ε4) 
with different effects on lipid and neuronal 
homeostasis (Phillips 2014). Epidemiologic 
studies have identified that these isoforms are 
the main genetic determinants of the progres-
sion of AD (Holtzman et al., 2012). For ex-
ample, individuals carrying the ε4 allele are at 
increased risk of AD when compared with 
those carrying the more common ε3 allele, 
whereas the ε2 allele decreases risk (Liu et al., 
2013). In addition to the polymorphism 
within the coding region, uncovering the pol-
ymorphisms within the APOE promoter re-
gion may also be beneficial to predict AD 
risk.  
The APOE gene encodes apolipoprotein E 
(APOE) and has a promoter region that is 
complex, with several regulatory elements lo-
cated in the proximal 5’ flanking region and 
the first intron of the human APOE gene 
(Berg et al., 1995; Garcia et al., 1996). Thus, 
polymorphisms in this region could have 
functional repercussions mediated by the reg-
ulation of APOE gene transcription. Three 
single nucleotide polymorphisms (SNPs), at  
-491 (A/T, rs449647), -427 (T/C, rs769446) 
and -219 (T/G, rs405509) upstream from the 
+1 transcription start site have been identi-
fied. These SNPs might influence APOE tran-
scriptional activity through differential bind-
ing of transcription factors (Sala Frigerio and 
De Strooper 2016). Although several studies 
have estimated the effect of APOE gene vari-
ants in the promoter region on AD suscepti-
bility, the results remain inconsistent. There-
fore, we conducted a systematic review of the 
literature and meta-analysis to evaluate the 
current status of the association between pol-
ymorphisms in the promoter region of the 
APOE gene and the risk of AD. 
 
MATERIALS AND METHODS 
Identification of eligible studies 
A comprehensive literature search was 
conducted using the online databases of Pub-
Med, Web of Science, Embase, Wanfang, and 
CNKI (China National Knowledge Infra-
structure) to retrieve relevant articles pub-
lished until November 2016. The Medical 
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Subject Heading (MeSH) terms were: “Alz-
heimer’s disease” or “Alzheimer” and 
“apolipoprotein E” or “APOE,” and “poly-
morphism” or “single nucleotide polymor-
phism” or “single nucleotide variant”.  
The corresponding Chinese characters 
were used in the Chinese databases. Refer-
ences were manually checked to obtain more 
relevant articles. Studies written in English or 
in Chinese language were included. When the 
same authors or laboratories published more 
than one article that included the same study 
participants, only the most complete study 
was included into the meta-analysis. 
 
Criteria for article screening 
The eligible articles had to meet the fol-
lowing inclusion criteria: 1) case-control 
studies evaluating the relationship between 
polymorphisms in the promoter region of the 
APOE gene and susceptibility to Alzheimer’s 
disease (AD); 2) diagnosis of patients with 
AD based on standards of the National Insti-
tute of Neurological and Communicative Dis-
orders and Stroke (NINCDS) or Alzheimer’s 
Disease and Related Disorders Association 
(ADRDA) working group (McKhann et al., 
1984); 3) inclusion of age-matched controls 
of unrelated participants without dementia; 4) 
results that were expressed as an odds ratio 
(OR) with corresponding 95 % confidence in-
terval (95 % CI); and 5) distribution of the 
genotype of controls for each polymorphism 
were required to be in Hardy–Weinberg equi-
librium (HWE).  
The exclusion criteria were: 1) review ar-
ticle or conference papers; 2) studies without 
a control group; 3) studies with duplicated 
data; 4) inability to extract the study data; and 
5) a study population that included patients 
with dementia due to causes other than AD. 
 
Quality assessment and data extraction 
Two authors independently assessed the 
quality of the extracted publications based on 
the study inclusion and exclusion criteria. 
Any disagreement was resolved by discussion 
with the third author, with each item dis-
cussed until a final consensus was reached. 
The following information was retrieved: 
name of the first author, publication year, 
country, mean patient age, number of cases 
and controls, distribution of genotypes, diag-
nostic criteria of AD, sources of controls, and 
genotyping methods. 
 
Statistical analysis 
Statistical analysis was carried out using 
the Stata 12.0 statistical software package 
(StataCorp, USA). The relationship between 
the APOE gene promoter polymorphisms and 
the risk of AD were evaluated by odds ratio 
(OR) with 95 % confidence interval (95 % 
CI). The significance of the pooled OR was 
determined by the Z-test. A P-value less than 
0.05 was considered to be significant.  
For each genetic variant, the allelic model, 
the homogeneous model, the heterogeneous 
model, the domain model, and the recessive 
model were calculated. Cochran’s Q test and 
the I2 test were employed to evaluate the het-
erogeneity of the included articles. The fixed-
effect model was used when the P-value of 
Cochran’s Q test was more than 0.10, and I2 
of the I2 test was less than 50 %; otherwise, 
the random-effect model was used. To assess 
whether our results were substantially influ-
enced by the presence of any individual study, 
we conducted a sensitivity analysis by sys-
tematically omitting each study and recalcu-
lating the significance of the result. Egger’s 
test and Begg’s test were performed to exam-
ine the publication bias.  
 
RESULTS 
Characteristics of eligible studies 
We first identified 500 relevant publica-
tions on APOE gene polymorphisms and the 
risk of Alzheimer’s disease (AD). However, 
after applying the study inclusion and exclu-
sion criteria, a total of 23 publications were 
finally included for study and included 5,703 
patients with AD, and 5,692 controls.  
Figure 1 shows the selection process of 
this meta-analysis. The 23 articles included 
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studies that were conducted in 16 countries: 
three in USA (Nicodemus et al., 2004; Parker 
et al., 2005; Tycko et al., 2004); two in China 
(Wang et al., 2017; Yang et al., 2003), two in 
Tunisia (Achouri-Rassas et al., 2014, 2015), 
one in France (Verpillat, 2000), two in Italy 
(Bizzarro et al., 2009; Licastro et al., 1999), 
two in Japan (Kimura et al., 2000; Toji et al., 
1999), two in the UK (Belbin et al., 2007; 
Lambert et al., 1998), one in Canada (Song et 
al., 1998), one in Australia (Laws et al., 
1999), one in Spain (Alvarez-Arcaya et al., 
2001), one in the Netherlands (Roks et al., 
2002), one in Hungary (Juhász et al., 2005), 
one in Brazil (Bahia et al., 2008), one in Slo-
vakia (Trebuňová et al., 2009), one in Korea 
(Chung et al., 2013), and one in Poland 
(Limon-Sztencel, 2016). 
Three polymorphic sites in the promoter 
region of APOE gene were reported: 
rs449647 (-491A/T), rs769446 (-427T/C) and 
rs405509 (-219T/G). All specimens were 
from blood samples. The sample size ranged 
from 105 to 1082. The genotype distributions 
in the controls of all studies were in agree-
ment with the Hardy–Weinberg equilibrium 
(HWE). The main characteristics of included 
studies are presented in Table 1. 
 
Association between rs449647 (-491A/T) 
APOE gene polymorphism and the risk of 
AD  
There were 19 published studies that in-
cluded the rs449647 (-491A/T) APOE gene 
polymorphism and the risk of AD. Between-
study heterogeneity was found, and the ran-
dom-effect model was employed to synthe-
size these data. Summary odds ratios (ORs) 
and tests for heterogeneity of published stud-
ies are shown in Table 2.  
 
Figure 1: Flow chart of publication selection process in literature review and meta-analysis 
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The T allele of rs449647 polymorphism 
was not associated with increased risk of AD 
when compared with the A allele (T vs. A: OR 
= 0.962, 95 % CI = 0.742–1.247, P = 0.769). 
This non-significant relationship was ob-
served in other genetic models as well (TT vs. 
AA: OR = 1.11, 95 % CI = 0.891–1.382, P = 
0.352; TT vs. AT: OR = 1.02, 95 % CI = 
0.699–1.49, P = 0.918; AT+TT vs. AA: OR = 
0.941, 95 % CI = 0.723–1.225, P = 0.651; TT 
vs. AA+AT: OR = 0.928, 95 % CI = 0.583–
1.478, P = 0.753).  
Subgroup analysis by ethnicity showed 
that there was a significant difference be-
tween Asian and non-Asian patients with AD 
and effects of rs449647 polymorphism and 
AD risk (P < 0.0001), as shown in Figure 2A. 
Subgroup analysis by diagnostic criteria 
for patients with AD showed that there was a 
significant difference for selection criteria in 
each study, as shown in Figure 2B. 
Subgroup analysis by participants in the 
control groups showed that there was a signif-
icant difference between healthy individuals 
and patients in the control groups, as shown 
in Figure 2C. 
 
 
Figure 2: Subgroup analysis of the association between rs449647 polymorphism and suscep-
tibility to Alzheimer’s disease (AD)  
A: ethnicity 
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Figure 2 (cont.): Subgroup analysis of the association between rs449647 polymorphism and 
susceptibility to Alzheimer’s disease (AD)  
B: diagnostic criteria of patients with AD; C: participants in the control groups 
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Table 1: Characteristics of the included studies and patient baseline demographics 
Authors Year Coun-
try 
Diagnostic criteria of 
patients with AD 
Sources of controls Sample 
size 
Mean age Genotyp-
ing 
method 
HWE 
in 
con-
trols 
     AD/ 
Control 
AD/control   
Song et al. 1998 Canada NINCDS/ADRDA criteria cognitively normal 88/120 76.1±7.8/69.6±12.5 nested 
PCR 
Y 
Lambert et 
al. 
1998 France DSM-III-R and NINDCS-
ADRDA criteria 
without DMS-III-R dementia cri-
teria and with integrity of their 
cognitive functions 
573/509 73.8±8.1/74.3±9.9 nested 
PCR 
Y 
Licastro et 
al. 
1999 Italy NINCDS/ADRDA and DMS–
III–R criteria 
non-demented controls 260/186 75±1/60±1 nested 
PCR 
Y 
Toji et al. 1999 Japan NINCDS/ADRDA criteria healthy controls 118/118 67.6±9.5/65.1±8.5 nested 
PCR 
Y 
Laws et al. 1999 Aus-
tralia 
NINCDS/ADRDA criteria healthy individuals 232/406 - nested 
PCR 
Y 
Zurutuza 
et al. 
2000 France NINCDS/ADRDA criteria none of them showed symptoms 
of dementia 
388/386 65.4±9.4/66.9±10.4 nested 
PCR 
Y 
Kimura et 
al. 
2000 Japan NINCDS/ADRDA criteria cognitively healthy 216/157 75.1±9.4/74.5±5.4 nested 
PCR 
Y 
Alvarez-
Arcaya et 
al. 
2001 Spain NINCDS/ADRDA criteria free of significant illness and had 
Mini Mental State Examination 
scores of 28 or more, which 
were verified by at least one sub-
sequent annual following-up as-
sessment 
251/251 75.3±9.3/79.9±7.9 nested 
PCR 
Y 
Roks et al. 2002 The 
Nether-
lands 
NINCDS/ADRDA criteria without dementia  360/247 82.4±7.1/74.7 ±3.6 nested 
PCR 
Y 
Yang et al. 2003 China NINCDS/ADRDA criteria good physical and mental health 183/133 74.6±/74.5 nested 
PCR 
Y 
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Authors Year Coun-
try 
Diagnostic criteria of 
patients with AD 
Sources of controls Sample 
size 
Mean age Genotyp-
ing 
method 
HWE 
in 
con-
trols 
     AD/ 
Control 
AD/control   
Nicode-
mus et al. 
2004 USA DSM-III-R and NINDCS-
ADRDA criteria 
unrelated controls (mostly 
spouses of AD patients) 
547/298 80 years or greater nested 
PCR 
Y 
Tycko et 
al. 
2004 USA NINDS-ADRDA criteria healthy Medicare beneficiaries 372/610 aged 65 years or older HhaI 
PCR 
Y 
Parker et 
al. 
2005 USA NINCDS/ADRDA criteria spouses of patients and of sib-
lings of similar age, ethnic back-
ground, and similar environmen-
tal exposure were used as con-
trols 
 
180/141 70.78±8.07/72.27±8.42 nested 
PCR 
Y 
Juhász et 
al. 
2005 Hungary DSM-IV and NINCDS-
ADRDA criteria 
spouses of the demented pro-
bands and none of them had 
verified symptoms of dementia 
52/53 73±8.9/71.5±7.0 nested 
PCR 
Y 
Belbin et 
al. 
2007 UK CERAD criteria CERAD criteria 395/324 75.6±10.5/75.3±9.4 nested 
PCR 
Y 
Bahia et 
al. 
2008 Brazil NINCDS/ADRDA criteria no evidence of neurologic or 
psychiatric impairment, or sys-
temic decompensated disease 
220/220 75.2±9.2/72.5±8.6 nested 
PCR 
Y 
Trebuňová 
et al. 
2009 Slovakia NINCDS/ADRDA criteria cognitively healthy 69/122 73.26±9.98/73.20±10.75 nested 
PCR 
Y 
Chung et 
al. 
2013 Korea NINCDS/ADRDA criteria good physical and mental health 290/554 74.86±9.14/64.68±9.26 nested 
PCR 
Y 
Bizzarro et 
al. 
2009 Italy NINDS-ADRDA criteria no personal or familial psychiat-
ric or cognitive impairment his-
tory, and no alcohol or drug 
abuse were reported, and  
MMSE score 428/30 
169/99 63.38±7.39 /66.21±7.31 nested 
PCR 
Y 
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Authors Year Coun-
try 
Diagnostic criteria of 
patients with AD 
Sources of controls Sample 
size 
Mean age Genotyp-
ing 
method 
HWE 
in 
con-
trols 
     AD/ 
Control 
AD/control   
Achouri-
Rassas et 
al. 
2014 Tunisia DSM-IV criteria good physical and mental health 85/90 73.00±9.09/70±15 nested 
PCR 
Y 
Wang et 
al. 
2017 China NINCDS/ADRDA criteria good physical and mental health 460/468 80.8±16.7/81.9±16.1 nested 
PCR 
Y 
Achouri-
Rassas et 
al. 
2015 Tunisia DSM-IV criteria good physical and mental health 85/90 72.36±9.77/69.12±14.56 nested 
PCR 
Y 
Limon-
Sztencel 
2016 Poland medical interviews, clinical 
symptoms and appropriate 
imaging examinations and 
clinical scales 
no signs or symptoms of demen-
tia or a severe somatic disorder 
healthy volunteers 
110/110 71.2±9/66.8±7.5 Sanger 
sequenc-
ing 
Y 
HWE, Hardy-Weinberg Equilibrium; NINCDS, National Institute of Neurological and Communicative Disorders and Stroke; ADRDA, the Alzheimer’s Disease and Related Disorders Association 
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Table 2: The pooled analysis between polymorphisms in the promoter region of APOE gene and risk of Alzheimer’s disease (AD)  
SNPs Comparisons Test of association Test of 
heterogeneity 
Publication bias 
 exposure 
factor 
unexposure  
factor 
OR Lower 
Limit 
Upper 
Limit 
P (OR) I2 Ph P (Begg's Test) P (Egger's test) 
rs449647 
(A/T) 
TT AA 1.11 0.891 1.382 0.352 0.74 0.0001 0.484 0.253 
TT AT 1.02 0.699 1.49 0.918 0.515 0.005 0.036 0.368 
TT AA+AT 0.928 0.583 1.478 0.753 0.71 0.0001 0.327 0.172 
AT+TT AA 0.941 0.723 1.225 0.651 0.841 0.0001 0.401 0.577 
T A 0.962 0.742 1.247 0.769 0.883 0.0001 0.441 0.894 
rs769446 
(T/C) 
CC TT 0.632 0.385 1.01 0.055 0 0.627 0.858 0.604 
CC TC 0.778 0.477 1.27 0.316 0 0.734 0.529 0.783 
CC TT+TC 0.66 0.413 1.055 0.083 0 0.687 0.858 0.683 
CC+CT TT 0.947 0.714 1.256 0.708 0.687 0.001 0.371 0.788 
C T 1.271 1.114 1.449 < 0.0001 0.314 0.157 0.474 0.218 
rs405509 
(T/G) 
TT GG 0.868 0.519 1.519 0.59 0.881 0.0001 0.032 0.006 
TT TG 0.924 0.681 1.255 0.614 0.706 0.0001 0.032 0.017 
TT TG+GG 0.892 0.608 1.31 0.56 0.836 0.0001 0.032 0.018 
TT+TG GG 0.969 0.715 1.313 0.84 0.848 0.0001 0.049 0.04 
T G 0.947 0.738 1.216 0.671 0.896 0.0001 0.032 0.004 
EXCLI Journal 2017;16:921-938 – ISSN 1611-2156 
Received: March 20, 2017, accepted: June 09, 2017, published: June 20, 2017 
 
 
931 
Association between rs769446 (-427T/C) 
APOE gene polymorphism and risk of AD  
There were ten published studies that in-
cluded rs769446 (-427T/C) APOE gene poly-
morphism and risk of AD. Our results found 
that the C allele of rs769446 variant was as-
sociated with an increase of risk of AD under 
the allelic model (C vs. T: OR = 1.271, 95 % 
CI = 1.114–1.449, P < 0.0001) as shown in 
Figure 3. However, this variant was not asso-
ciated with AD under other genetic models 
(CC vs. TT: OR = 0.632, 95 % CI = 0.385–
1.01, P = 0.055; CC vs. TC: OR = 0.778, 95 % 
CI = 0.477–1.27, P = 0.316; CC+CT vs. TT: 
OR = 0.947, 95 % CI = 0.714–1.256, P = 
0.708; CC vs. TT+TC: OR = 0.66, 95 % CI = 
0.413–1.055, P = 0.083). 
 
Association between rs405509 (-219G/T) 
APOE gene polymorphism and risk of AD  
There were ten published studies that in-
cluded rs405509 (-219G/T) APOE gene poly-
morphism and risk of AD. No significant as-
sociation was detected between this variant 
and AD risk under each genetic model (T vs. 
G: OR = 0.947, 95 % CI = 0.738–1.216, P = 
0.671; TT vs. GG: OR = 0.868, 95 % CI = 
0.519–1.519, P = 0.59; TT vs. TG: OR = 
0.924, 95 % CI = 0.681–1.255, P = 0.614; 
TT+TG vs. GG: OR = 0.969, 95 % CI = 
0.715–1.313, P = 0.84; TT vs. TG+GG: OR = 
0.892, 95 % CI = 0.608–1.31, P = 0.56). 
 
Sensitivity analysis and publication bias 
To observe whether the results were influ-
enced by each of the included studies, we sys-
tematically deleted each single article at a 
time. The results showed that the overall re-
sults were not significantly changed, as 
shown in Figure 4.  
Begg's test and Egger's test were used to 
assess the publication bias of the literature. 
Except for rs405509 variant, there was no ev-
idence of publication bias in other genetic 
comparisons in our study, as shown in Figure 
5. These results supported that the publication 
bias was low in the present meta-analysis. 
 
Figure 3: Forest plot of rs769446 polymorphism and risk for Alzheimer’s disease (AD) under the allelic 
model 
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Figure 4: Sensitivity analysis of these three genetic polymorphisms in the promoter region of ApoE gene 
in AD risk (A: rs449647; B: rs769446) 
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Figure 4 (cont.): Sensitivity analysis of these three genetic polymorphisms in the promoter region of 
ApoE gene in AD risk (C: rs405509) 
 
 
Figure 5: Begger’s plot of rs769446 polymorphism in AD risk under the allelic model 
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DISCUSSION 
In this meta-analysis, we were able to 
identify 23 eligible publications on APOE 
gene polymorphisms and risk of Alzheimer’s 
disease (AD) that satisfied the inclusion crite-
ria of the study. The results showed that only 
the C allele of rs769446 polymorphism in the 
promoter region of APOE gene was associ-
ated with an increased risk of AD when com-
pared with the T allele.  
Rs449647 and rs405509 polymorphisms 
of APOE gene were not associated with AD 
risk under each genetic comparison model. 
These results differ from the previous meta-
analysis conducted by Xin et al. (2010), 
which confirmed a significant but modest as-
sociation between APOE promoter -491A/T 
and -219T/G polymorphisms and AD suscep-
tibility. 
AD is a complex disease resulting from 
the interaction between genetic and environ-
mental factors. A major function of ApoE is 
to mediate the binding of lipoproteins or lipid 
complexes in the plasma or interstitial fluids 
to specific cell-surface receptors (Huang and 
Mahley, 2014). Reduced levels of plasma 
APOE have been shown to be significantly 
correlated with reduced hippocampal size, 
which may reflect a component of the neuro-
pathology of AD in elderly individuals (Teng 
et al., 2015).  
APOE gene isoforms can differentially in-
fluence total serum cholesterol levels that 
support lipid transport and injury repair in the 
brain, and its genotypes are considered to be 
genetic risk factors for AD susceptibility. 
Published data supports that APOE ɛ4 leads to 
synaptic deficits and impairment in long-term 
potentiation, memory, and cognition (Kim et 
al., 2014). The APOE ɛ4 genotype has been 
shown to be the strongest single genetic factor 
associated with cerebrospinal fluid APOE 
protein levels, and APOE protein levels in 
cerebrospinal fluid may be a useful pheno-
typic biomarker for AD risk (Cruchaga et al., 
2012). Also, serum ApoE was shown to be as-
sociated with long-term risk of AD in the gen-
eral population, independent of APOE geno-
type (Wolters et al., 2016). APOE gene ex-
pression level is a risk factor for AD irrespec-
tive of APOE ε4 allele status.  
Variations in levels of APOE have been 
tied to the risk and progression of AD. A pre-
vious meta-analysis has shown that APOE lo-
cus reached genome-wide significance in AD 
risk (P < 5×10−8) (Lambert et al., 2013). The 
APOE promoter genetic variants may influ-
ence the gene transcription level, thus involv-
ing in the progression of AD.  
The -491AA polymorphism in the APOE 
gene was shown to be associated with in-
creased plasma ApoE levels in patients with 
AD (Laws et al., 1999). Artiga et al. (1998) 
have shown that polymorphisms at sites -491 
and -219 of the APOE promoter produced 
variations in the transcriptional activity of this 
gene, most likely through differential binding 
of nuclear proteins. Maloney et al. (2010) 
found that the -219 and -491 polymorphic 
variations were significantly associated with 
the incidence of AD and -491 AA was signif-
icantly associated with increased risk even 
when stratified for the APOE ε4 allele. Wang 
et al. (2000) showed that the -491 AA geno-
type appeared to be an independent genetic 
risk factor for AD. Nicodemus et al. (2004) 
demonstrated that the -219 T allele (P = 
0.009) was associated with increased risk of 
AD in age-stratified analysis in patients with 
AD at age of onset of 80 years or more and 
age-matched controls. Lambert et al. (2004) 
found that -219 G/T promoter polymorphism 
influenced binding to the estrogen receptor 
and altered transcriptional activity in response 
to estrogen, possibly being involved in in-
creased risk for AD in women bearing an ε4 
allele. Bizzarro et al. (2009) have confirmed 
the role of the -491 AA genotype as a risk fac-
tor for AD in Italy and suggested that pro-
moter genotypes and APOE haplotypes might 
have a complex function in AD-associated ge-
netic risk factors. 
Other genetic variants may also be associ-
ated with increased risk of AD. The presence 
of an APOE ε4 allele has been shown to have 
a more deleterious effect on younger patients 
with AD when compared with older patients 
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with AD on cognition and brain structure both 
in cross-sectional and longitudinal studies 
(Chang et al., 2014). APOE gene status and 
family history of dementia and AD have been 
shown to be significantly associated with am-
yloid load; the APOE genotype appears to be 
an important driver of amyloid levels (Vemuri 
et al., 2013).  
Some familiar generic drugs (such as 
gene-based, alternate approach) have known 
safety profiles that can deter unexpected risks. 
Researchers have suggested that APOE geno-
type status can be safely and effectively dis-
closed to individuals at high risk of AD (Scott 
Roberts and Green, 2015). In mouse models, 
APOE-directed treatments were shown to rap-
idly clear β-amyloid and reverse neurological 
deficits in AD (Cramer et al., 2012). In pa-
tients with AD, the APOE genotype may 
modify therapeutic responses (Hanson et al., 
2015). Studies have also identified that poten-
tial APOE inducer agents could be used in 
vivo for the treatment, and possibly the pre-
vention of sporadic AD (Poirier et al., 2014).  
There were several limitations to this 
study. First, there was high between-study 
heterogeneity observed, which could have af-
fected the accuracy of the results. Second, the 
diagnostic criteria for AD in the patients and 
the condition of the controls in the retrieved 
publications were not consistent. Third, other 
factors such as environmental risk factors, 
gender, sex, and age, could not be considered 
due to lack of details in the publications. Un-
derstanding these risk factors and protective 
factors of AD is important for developing in-
dividualized interventions for the prevention 
and treatment of AD. 
In conclusions, the findings of this meta-
analysis showed that rs769446 polymorphism 
in the APOE gene promoter region could be a 
possible risk factor for AD. Future large, 
well-designed, multicenter, controlled clini-
cal studies are still needed to explore further 
the relationship between variants of APOE 
gene promoter region and risk of developing 
AD. 
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